BioSpace News Archive

Pharnext will present, in a poster and during an oral session, an update on its ongoing pivotal Phase 3 clinical trial evaluating its lead PLEODRUG PXT3003.

PDL BioPharma today issued the following statement in response to the Neos Board of Directors’ rejection of PDL’s October 26 proposal to acquire Neos for $10.25 per share in cash.

Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will host a conference call to discuss the results.

Incyte Corporation today announced the appointment of Jacqualyn Fouse, Ph.D., as a new member of the Board of Directors, effective November 14, 2017.

Of the 19 patients implanted in The INSPIRE Study to date, 16 patients are in follow-up, 14 of whom have reached the six-month primary endpoint visit.

The Company will conduct an earnings call at 8:00 am EST on Wednesday, November 8, 2017, where senior management will discuss the Company’s performance and answer questions from participants.

Revenues for the third quarter of 2017 decreased three percent to $44M, compared to $45.3M for the third quarter of 2016.

Sales in the first six months of FY2017 decreased by 1.8% compared to those in the corresponding period of the previous fiscal year (“year-on-year”) to JPY639.8 billion due to the impact of certain items such as the transfer of the global dermatology business in April 2016 and the transfer of long-listed products in Japan in April 2017.

The company will host a webcast and conference call to discuss the company’s financial results the same day.

In the presentation, Ronin explained its belief that, given the Company’s abysmal performance under the leadership of long-standing incumbent directors Carlton M. Johnson Jr., Steven W. King, David H. Pohl and Eric S. Swartz, a complete overhaul of the boardroom is warranted.